Dishman Carbogen Amcis Limited (NSE:DCAL)
India · Delayed Price · Currency is INR 237.95
-4.40 (-1.82%)
Nov 21, 2025, 3:29 PM IST
Dishman Carbogen Amcis Revenue
Dishman Carbogen Amcis had revenue of 6.53B INR in the quarter ending September 30, 2025, a decrease of -17.29%. This brings the company's revenue in the last twelve months to 27.59B, up 5.38% year-over-year. In the fiscal year ending March 31, 2025, Dishman Carbogen Amcis had annual revenue of 27.12B with 3.66% growth.
Revenue (ttm)
27.59B
Revenue Growth
+5.38%
P/S Ratio
1.35
Revenue / Employee
24.95M
Employees
1,106
Market Cap
37.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 27.12B | 957.30M | 3.66% |
| Mar 31, 2024 | 26.16B | 2.03B | 8.41% |
| Mar 31, 2023 | 24.13B | 2.72B | 12.72% |
| Mar 31, 2022 | 21.41B | 2.29B | 11.96% |
| Mar 31, 2021 | 19.12B | -1.32B | -6.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Dishman Carbogen Amcis News
- 9 days ago - Q2 2026 Dishman Carbogen Amcis Ltd Earnings Call Transcript - GuruFocus
- 5 months ago - Dishman Carbogen clears US FDA inspection at Naroda facility with no observations - Business Upturn
- 6 months ago - Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement - Business Upturn
- 6 months ago - Dishman Carbogen Amcis shares surge over 11% as company swings to profit in Q4, EBITDA margin doubles - Business Upturn
- 8 months ago - Dishman Carbogen shares surge 5% after arm gets drug manufacturing licence In China - Business Upturn
- 8 months ago - Dishman Carbogen Amcis subsidiary receives drug manufacturing license in China - Business Upturn
- 9 months ago - Dishman Carbogen Amcis shares jump nearly 2% after board approves Rs 50 crore debenture issuance - Business Upturn
- 10 months ago - Q3 2025 Dishman Carbogen Amcis Ltd Earnings Call Transcript - GuruFocus